HRP20201370T1 - Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule - Google Patents
Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule Download PDFInfo
- Publication number
- HRP20201370T1 HRP20201370T1 HRP20201370TT HRP20201370T HRP20201370T1 HR P20201370 T1 HRP20201370 T1 HR P20201370T1 HR P20201370T T HRP20201370T T HR P20201370TT HR P20201370 T HRP20201370 T HR P20201370T HR P20201370 T1 HRP20201370 T1 HR P20201370T1
- Authority
- HR
- Croatia
- Prior art keywords
- infection
- bispecific antibody
- pseudomonas
- pcrv
- subject
- Prior art date
Links
- 241000589516 Pseudomonas Species 0.000 title claims 3
- 238000002648 combination therapy Methods 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 claims 4
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010051548 Burn infection Diseases 0.000 claims 1
- 206010061788 Corneal infection Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000001860 Eye Infections Diseases 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 241000168225 Pseudomonas alcaligenes Species 0.000 claims 1
- 241000589540 Pseudomonas fluorescens Species 0.000 claims 1
- 241000589776 Pseudomonas putida Species 0.000 claims 1
- 206010048038 Wound infection Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000011323 eye infectious disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Bispecifično protutijelo koje sadrži vezujuću domenu koja se veže na Pseudomonas Psl i vezujuću domenu koja se veže na Pseudomonas PcrV, pri čemu bispecifično protutijelo sadrži anti-PcrV teškog lanca-anti-Psl scFv fuzijski protein, pri čemu je Psl scFv unutar zglobnog područja anti-PcrV teškog lanca, navedeni fuzijski protein ima aminokiselinsku sekvencu navedenu u SEQ ID NO: 264 i anti-PcrV lakog lanca ima aminokiselinsku sekvencu navedenu u SEQ ID NO: 263.
2. Izolirana polinukleotidna molekula naznačena time što sadrži sekvencu nukleinske kiseline koji kodira bispecifično protutijelo iz zahtjeva 1.
3. Pripravak naznačen time što sadrži bispecifično protutijelo prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač.
4. Pripravak prema patentnom zahtjevu 3, naznačen time što nadalje sadrži antibiotik.
5. Pripravak prema patentnom zahtjevu 4, naznačen time što je antibiotik odabran iz skupine koja sadrži ciprofloksacin, meropenem, i njihovu kombinaciju.
6. Pripravak prema bilo kojem od patentnih zahtjeva 3 do 5 naznačen time što se upotrebljava za sprječavanje ili liječenje Pseudomonas infekcije kod subjekta kojem je to potrebno.
7. Komplet naznačen time što sadrži pripravak prema bilo kojem od zahtjeva 3 do 5.
8. Bispecifično protutijelo ili njegov ulomak prema patentnom zahtjevu 1 naznačeno time što se upotrebljava u sprječavanju ili liječenju Pseudomonas infekcije kod subjekta.
9. Bispecifično protutijelo za uporabu prema patentnom zahtjevu 8, naznačeno time što je subjekt čovjek.
10. Bispecifično protutijelo za uporabu prema patentnom zahtjevu 8 ili 9, naznačeno time što Pseudomonas infekcija je infekcija s P. aeruginosa, Pseudomonas fluorescens, Pseudomonas putida, ili Pseudomonas alcaligenes.
11. Bispecifično protutijelo za uporabu prema bilo kojem od patentnih zahtjeva 8 do 10, naznačeno time što je infekcija očna infekcija, plućna infekcija, infekcija opeklinom, infekcija rane, kožna infekcija, infekcija krvi, infekcija kosti ili kombinacija dvije ili više navedenih infekcija.
12. Bispecifično protutijelo za uporabu prema bilo kojem od patentnih zahtjeva 8 do 10, naznačeno time što subjekt ima akutnu upalu pluća, ozljedu od opekline, infekciju rožnice, cističnu fibrozu ili njihovu kombinaciju.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556645P | 2011-11-07 | 2011-11-07 | |
| US201261625299P | 2012-04-17 | 2012-04-17 | |
| US201261697585P | 2012-09-06 | 2012-09-06 | |
| EP12847479.8A EP2776065B1 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
| PCT/US2012/063722 WO2013070615A1 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201370T1 true HRP20201370T1 (hr) | 2020-11-27 |
Family
ID=48290482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201370TT HRP20201370T1 (hr) | 2011-11-07 | 2020-08-28 | Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10597439B2 (hr) |
| EP (1) | EP2776065B1 (hr) |
| JP (1) | JP6182152B2 (hr) |
| KR (1) | KR102184343B1 (hr) |
| CN (1) | CN104136042B (hr) |
| AU (3) | AU2012336028A1 (hr) |
| BR (1) | BR112014011028B1 (hr) |
| CA (2) | CA2854817C (hr) |
| CY (1) | CY1123552T1 (hr) |
| DK (1) | DK2776065T3 (hr) |
| ES (1) | ES2859323T3 (hr) |
| HK (1) | HK1201453A1 (hr) |
| HR (1) | HRP20201370T1 (hr) |
| HU (1) | HUE050985T2 (hr) |
| LT (1) | LT2776065T (hr) |
| MX (1) | MX2014005566A (hr) |
| PL (1) | PL2776065T3 (hr) |
| PT (1) | PT2776065T (hr) |
| RS (1) | RS60920B1 (hr) |
| RU (1) | RU2687588C2 (hr) |
| SI (1) | SI2776065T1 (hr) |
| WO (1) | WO2013070615A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57024B1 (sr) | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
| LT2776065T (lt) * | 2011-11-07 | 2020-10-12 | Medimmune Limited | Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules |
| CA2863468A1 (en) * | 2012-03-02 | 2013-09-06 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
| CA2888211A1 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| JP2016524606A (ja) * | 2013-05-14 | 2016-08-18 | メディミューン，エルエルシー | 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＰｓｌエキソ多糖の合成オリゴ糖サブユニットおよびその使用 |
| EP3139950A4 (en) * | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
| TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| ES2846881T3 (es) * | 2015-05-01 | 2021-07-30 | Inhibrx Inc | Moléculas que se dirigen al sistema de secreción de tipo III |
| US20170073397A1 (en) * | 2015-08-24 | 2017-03-16 | Medimmune, Llc | MrkA Polypeptides, Antibodies, and Uses Thereof |
| JP7110095B2 (ja) * | 2015-11-30 | 2022-08-01 | メドイミューン・リミテッド | 院内肺炎を予防または治療する方法 |
| EP3452090A4 (en) * | 2016-05-05 | 2019-12-18 | The Trustees of The University of Pennsylvania | CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST PSEUDOMONAS AERUGINOSA |
| BR112021023335A2 (pt) | 2019-06-11 | 2022-01-04 | Regeneron Pharma | Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística |
| BR112021026788A2 (pt) * | 2019-07-09 | 2022-05-10 | Staidson Beijing Biopharmaceuticals Co Ltd | Anticorpos que reconhecem especificamente pcrv de pseudomonas e usos dos mesmos |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2021244421A1 (en) * | 2020-06-01 | 2021-12-09 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing pseudomonas pcrv and uses thereof |
| WO2022028444A1 (en) * | 2020-08-07 | 2022-02-10 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing pseudomonas psl and uses thereof |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| CN116621987A (zh) * | 2020-11-18 | 2023-08-22 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv或psl抗原的抗体组合以及双特异性抗体 |
| WO2023141611A2 (en) * | 2022-01-21 | 2023-07-27 | Lyvgen Biopharma Holdings Limited | Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation |
| WO2024003103A1 (en) | 2022-06-29 | 2024-01-04 | Astrazeneca Ab | Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| DE3685700T2 (de) | 1985-03-11 | 1993-03-11 | Teijin Ltd | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| WO1999004705A1 (en) | 1997-07-25 | 1999-02-04 | Tsui Ban C H | Devices, systems and methods for determining proper placement of epidural catheters |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| EP1666058B1 (en) | 1998-11-25 | 2011-12-28 | MCW Research Foundation, Incorporated | Method of diagnosing a Pseudomonas aeruginosa infection |
| WO2002102855A2 (en) | 2000-11-17 | 2002-12-27 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| JP4355786B2 (ja) | 2001-01-26 | 2009-11-04 | エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド | シュードモナスｖ抗原を用いる免疫化のための方法および組成物 |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20020146753A1 (en) | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
| US7119172B2 (en) | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
| US20030232387A1 (en) * | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
| US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| EP1928506A4 (en) | 2005-08-19 | 2009-10-21 | Abbott Lab | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7790862B2 (en) * | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
| JP2008133206A (ja) * | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
| US7553936B2 (en) * | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
| US9156914B2 (en) * | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| NZ586357A (en) * | 2007-11-30 | 2012-10-26 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| CA2711863C (en) * | 2008-01-10 | 2014-06-10 | Shionogi & Co., Ltd. | Antibody directed against pcrv |
| WO2009092011A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
| CA2742791A1 (en) | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN103398200B (zh) * | 2008-12-31 | 2015-09-23 | W.L.戈尔有限公司 | 通风装置 |
| WO2010091189A1 (en) * | 2009-02-04 | 2010-08-12 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
| SG10201400520WA (en) * | 2009-03-11 | 2014-05-29 | Shionogi & Co | Humanized pcrv antibody having anti-pseudomonal activity |
| WO2010107778A1 (en) * | 2009-03-18 | 2010-09-23 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
| CA3018235C (en) | 2009-03-20 | 2021-01-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| EP2417157A1 (en) | 2009-04-09 | 2012-02-15 | Kenta Biotech AG | Human monoclonal antibody specific for lipolysaccarides (lps) of serotype lats 01 of pseudomonas aeruginosa |
| CA2766405A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | Engineered fc regions for site-specific conjugation |
| CA2784033A1 (en) | 2009-12-22 | 2011-07-21 | Kalobios Pharmaceuticals, Inc. | A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
| CA2826566C (en) * | 2011-02-08 | 2022-09-13 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| WO2012145626A1 (en) | 2011-04-22 | 2012-10-26 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphylococcus vaccine |
| RS57024B1 (sr) * | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
| LT2776065T (lt) | 2011-11-07 | 2020-10-12 | Medimmune Limited | Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules |
| WO2013070565A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| CA2863468A1 (en) * | 2012-03-02 | 2013-09-06 | Ablynx Nv | Pseudomonas aeruginosa pcrv binding single variable domain antibodies |
| ES2912267T3 (es) * | 2012-11-06 | 2022-05-25 | Medimmune Llc | Métodos de tratamiento de enfermedades asociadas a S. aureus |
| CA2888211A1 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| AU2013341361A1 (en) * | 2012-11-06 | 2015-06-04 | Medimmune, Llc | Antibodies to S. aureus surface determinants |
| JP2016524606A (ja) | 2013-05-14 | 2016-08-18 | メディミューン，エルエルシー | 緑膿菌（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）のＰｓｌエキソ多糖の合成オリゴ糖サブユニットおよびその使用 |
| EP3139950A4 (en) * | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
| TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| JP7110095B2 (ja) * | 2015-11-30 | 2022-08-01 | メドイミューン・リミテッド | 院内肺炎を予防または治療する方法 |
| EP3452090A4 (en) * | 2016-05-05 | 2019-12-18 | The Trustees of The University of Pennsylvania | CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST PSEUDOMONAS AERUGINOSA |
| BR112021023335A2 (pt) * | 2019-06-11 | 2022-01-04 | Regeneron Pharma | Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística |
-
2012
- 2012-11-06 LT LTEP12847479.8T patent/LT2776065T/lt unknown
- 2012-11-06 KR KR1020147015274A patent/KR102184343B1/ko active IP Right Grant
- 2012-11-06 CN CN201280054651.8A patent/CN104136042B/zh active Active
- 2012-11-06 RU RU2014122990A patent/RU2687588C2/ru active
- 2012-11-06 WO PCT/US2012/063722 patent/WO2013070615A1/en active Application Filing
- 2012-11-06 PT PT128474798T patent/PT2776065T/pt unknown
- 2012-11-06 EP EP12847479.8A patent/EP2776065B1/en active Active
- 2012-11-06 US US14/356,500 patent/US10597439B2/en active Active
- 2012-11-06 RS RS20201211A patent/RS60920B1/sr unknown
- 2012-11-06 AU AU2012336028A patent/AU2012336028A1/en not_active Abandoned
- 2012-11-06 SI SI201231834T patent/SI2776065T1/sl unknown
- 2012-11-06 BR BR112014011028-0A patent/BR112014011028B1/pt active IP Right Grant
- 2012-11-06 PL PL12847479T patent/PL2776065T3/pl unknown
- 2012-11-06 CA CA2854817A patent/CA2854817C/en active Active
- 2012-11-06 HU HUE12847479A patent/HUE050985T2/hu unknown
- 2012-11-06 MX MX2014005566A patent/MX2014005566A/es active IP Right Grant
- 2012-11-06 JP JP2014540196A patent/JP6182152B2/ja active Active
- 2012-11-06 CA CA3161431A patent/CA3161431A1/en active Pending
- 2012-11-06 DK DK12847479.8T patent/DK2776065T3/da active
- 2012-11-06 ES ES12847479T patent/ES2859323T3/es active Active
-
2015
- 2015-02-27 HK HK15101962.5A patent/HK1201453A1/xx unknown
-
2017
- 2017-08-25 AU AU2017219081A patent/AU2017219081B9/en active Active
-
2019
- 2019-09-05 AU AU2019226205A patent/AU2019226205A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/789,790 patent/US11203633B2/en active Active
- 2020-08-28 HR HRP20201370TT patent/HRP20201370T1/hr unknown
- 2020-10-08 CY CY20201100949T patent/CY1123552T1/el unknown
-
2021
- 2021-11-15 US US17/454,837 patent/US20220177554A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201370T1 (hr) | Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule | |
| JP2017519768A5 (hr) | ||
| TWI719938B (zh) | 多重細菌感染之治療 | |
| Hernández-Jiménez et al. | Biofilm vs. planktonic bacterial mode of growth: which do human macrophages prefer? | |
| JP2021063090A5 (hr) | ||
| RU2011129204A (ru) | Антитела против ангиопоэтина-2 человека | |
| SI2780368T1 (en) | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A | |
| EA201500132A1 (ru) | Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний | |
| AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
| BR112014005799A2 (pt) | anticorpos para pcsk9, seus usos, e composição farmacêutica | |
| UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
| RS53174B (en) | USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE | |
| BRPI0615026A8 (pt) | imunoglobulina de domínio variável duplo e seus usos | |
| RU2009148286A (ru) | Жидкая фармацевтическая композиция ботулинического токсина | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| JP2011502137A5 (hr) | ||
| BR112013031485A2 (pt) | "anticorpos anti-psl de pseudomonas, seus método de produção e uso na prevenção ou no tratamento de infecção por pseudomonas, polinucleotídeo, 5 vetor, composição farmacêutica, bem como métodos in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais e para aumento de morte opsonofagocítica de p. aeruginosa" | |
| JP2016519124A5 (hr) | ||
| BR112014004704A2 (pt) | compostos antibacterianos e métodos de uso | |
| EA201200549A1 (ru) | Dll4-связывающие молекулы | |
| EA201992570A1 (ru) | Составы на основе человеческих антител к rankl, а также способы их применения | |
| EA200970586A1 (ru) | Антитела к цитомегаловирусу человека (hcmv) | |
| WO2008036761A8 (en) | Anti-microbial defensin-related peptides and methods of use | |
| MY161926A (en) | New antibiotic containing simulacrum antibody, preparation method and application thereof | |
| EA200702634A1 (ru) | Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения |